Clinical Trial

Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)

Study acronym: LiraGooD
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated January 13, 2025 (before its estimated January 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
The present 24-week, prospective, open-label, randomized, multicenter, parallel group trial is carried to investigate and evaluate the efficacy and safety of Liraglutide in combination with prandial insulin therapy vs insulin glargine in combination with prandial insulin therapy in overweight / obese patients with uncontrolled type 2 diabetes.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2017-03-16; most recent amendment 2025-01-09.
Trial Details
NCT Number NCT03087032
Lead Sponsor The First Affiliated Hospital of Xiamen University
Conditions Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic)
Enrollment 164 participants
Start Date 2019-01-10
Primary Completion 2025-01-15 (estimated)
Study Completion 2025-02-10 (estimated)
Updated on ClinicalTrials.gov 2025-01-13